Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-30
2009-11-17
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S046000, C514S047000, C514S048000
Reexamination Certificate
active
07618949
ABSTRACT:
The present invention provides a P2Y12receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Y12receptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Y12receptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 4330550 (1982-05-01), Lautenschlager et al.
patent: 4621076 (1986-11-01), Kuzuya et al.
patent: 5049550 (1991-09-01), Zamecnik
patent: 5292498 (1994-03-01), Boucher
patent: 5596088 (1997-01-01), Boucher et al.
patent: 5607836 (1997-03-01), Boucher et al.
patent: 5628984 (1997-05-01), Boucher
patent: 5635160 (1997-06-01), Stutts et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5656256 (1997-08-01), Boucher et al.
patent: 5681823 (1997-10-01), Kim et al.
patent: 5691156 (1997-11-01), Boucher et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5814609 (1998-09-01), Markland et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5902567 (1999-05-01), Boucher
patent: 5935555 (1999-08-01), Stutts et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 5958897 (1999-09-01), Jacobus et al.
patent: 5962432 (1999-10-01), La Croix et al.
patent: 5968913 (1999-10-01), LaCroix et al.
patent: 5972904 (1999-10-01), Jacobus et al.
patent: 5981506 (1999-11-01), Jacobus et al.
patent: 6022527 (2000-02-01), Boucher et al.
patent: 6037343 (2000-03-01), Ali
patent: 6040317 (2000-03-01), Duggan et al.
patent: 6133247 (2000-10-01), Boucher et al.
patent: 6143279 (2000-11-01), Boucher et al.
patent: 6159952 (2000-12-01), Shaffer et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6528640 (2003-03-01), Beigelman
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6908624 (2005-06-01), Hossainy et al.
patent: 7018985 (2006-03-01), Yerxa et al.
patent: 7101860 (2006-09-01), Boyer et al.
patent: 7132408 (2006-11-01), Boyer et al.
patent: 2005/0233062 (2005-10-01), Hossainy et al.
patent: 2006/0122143 (2006-06-01), Boyer et al.
patent: 1407903 (1995-10-01), None
patent: WO 89/04321 (1989-05-01), None
patent: WO 92/01673 (1991-07-01), None
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/08593 (1994-04-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 95/10538 (1995-04-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 97/29456 (1997-08-01), None
patent: WO 97/35591 (1997-10-01), None
patent: WO 98/03177 (1998-01-01), None
patent: WO 98/03182 (1998-01-01), None
patent: WO 98/15835 (1998-04-01), None
patent: WO 98/19685 (1998-05-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 98/34593 (1998-08-01), None
patent: WO 98/34942 (1998-08-01), None
patent: WO 99/01138 (1999-01-01), None
patent: WO 99/05155 (1999-02-01), None
patent: WO 99/09998 (1999-03-01), None
patent: WO 99/32085 (1999-07-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/30629 (2000-06-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 00/39145 (2000-07-01), None
patent: WO 00/50024 (2000-08-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
patent: WO 02/16381 (2002-02-01), None
patent: WO 2005/040174 (2005-05-01), None
patent: WO 2005/097814 (2005-10-01), None
patent: WO 2007/056213 (2007-05-01), None
Abbracchio et al., “International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy,”Pharmacol. Rev.; vol. 58(3): 281-341, Sep. 2006, p. 294, col. 2.
Aleil et al., “Flow Cytometric Analysis of Intraplatelet VASP Phosphorylation for the Detection of Clopidogrel Resistance in Patients with lschemic Cardiovascular Diseases,”J. Thromb. Haemost., vol. 3:85-92; 2005.
Alessi, D. et al., “Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and Its Interaction with Myosin and Skeletal Muscle”Biochemistry(1992), 31(34), 8043-54.
Antiplatelet Trialists' Collaboration., “Collaborative overview of randomised trials of antiplatelet therapy-I : Prevention of Death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients,”Br. Med. J. 308: 81-106 (1994).
Antiplatelet Trialists' Collaboration., “Collaborative overview of randomised trials of antiplatelet therapy-II : Maintenance of Vascular graft or arterial patency by antiplatelet therapy,”Br. Med. J. 308: 159-168 (1994).
Antman, E, for The TIMI 9a investigators, “Hirudin in Acute Myocardial Infarction,”,Circulation, 90(4):1624-1630 (1994).
Bennett et al., “Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel,”N. Engl. J. Med., 342: 1771-1777; 2000.
Bernat, A., et al., “Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat,”Thromb. Haemostas. (1993) 70(5):812-816.
Boyer et al., “Development of Reversible P2Y12 Receptor Antagonists,” 3rdIntl. Mtg., ADP 2004, Sep. 16-18, 2004, entire document.
Bujalowski, W. et al., “Structural Characteristics of the Nucleotide-Binding Site ofEscherichia coliPrimary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs”Biochemistry(1994), 33(15), 4682-94.
Bush, L., et al., “Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canie coronary arteries,” Circulation 69(6):1161-1170, (1984).
Cardullo, R. A. et al., “Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase”Analytical Biochemistry(1990), 188(2), 305-9.
Carvalho-Alves, P. et al., “Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase”Journal of Biological Chemistry(1985), 260(7), 4282-7.
Chapal, J. et al., “Comparative effects of adenosine-5′-triphosphate and related analogs on insulin secretion from the rat pancreas”Fundamental&Clinical Pharmacology(1997), 11(6), 537-545.
Conley et al., “Scientific and Therapeutic Insights into the Role of the Platelet P2Y12 Receptor in Thrombosis,”Current Opinion in Hematology; vol. 10:333338, Sep. 2003, p. 333 col. 1.
Doorty et al., “Poly(N-isopropylacrylamide) co-polymer films as potential vehicles for delivery of an antimitotic agent to vascular smooth muscle cells,”Cardiovascular Pathology12:105-110; 2003.
Douglass et al., INS50589, “A Potent, selective, and reversible inhibitor of P2Y12 mediated platelet aggregation,”, abstract P848086, 229thACS National Mtg, Mar. 13, 2005.
Douglass et al., “Effects of Ribose Modified Adenosine Phosphates in Models of Acute and Inflammatory Pain,” Poster presented at the 4thInt'l. Symposium of Nucleosides and Nucleotides Purines; Jun. 6-9, 2004, p. 1 col. 1.
EPIC investigators, “Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein Iib/IIIa Receptor in High-Risk Coronary Angioplasty,”New Engl. J. Med. (1994) 330:956-961.
Folts, J. et al., “Platelet Aggregation in Partially Obstructed Vessels and its Elimination with Asprian,” Circulation 54(3):365-370 (1976).
Frederick, L.G., et al.
Boyer José L.
Douglass, III James G.
Shaver Sammy R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick T
University of North Carolina at Chapel Hill
LandOfFree
Drug-eluting stents coated with P2Y 12 receptor antagonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug-eluting stents coated with P2Y 12 receptor antagonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug-eluting stents coated with P2Y 12 receptor antagonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144186